Newly on Gate2Biotech
Biosimilars - Pioneering the future
12.3.2012 | Newly on Gate2Biotech
Several biological drugs will go off patent over the next years. In fact, biologics with estimated total sales value of USD 63 bn (approx. 40% of forecast market) are expected to lose patent protection by 2015 globally, rising to more than USD 100 bn by 2020. The EU has been leading the world in the introduction of biosimilars since it approved...
Best Practices in Companion Diagnostics Collaborations
5.3.2012 | Newly on Gate2Biotech
Present situation of the market of personalized medicine has reached just a tip of the iceberg. There are obstacles to overcome all around the world, such as specific environments, different investment systems, popular one-size-fits-all treatment model, and above all – mutual assistance. As indicated by Frost&Sullivan, a renowned business and...
How to market your biotech company
16.2.2012 | Newly on Gate2Biotech
Biotech scientists are full of ideas. Some ideas are fanciful and never tested. Some ideas are tested and fail the tests. Others are tested and found to be worthy of implementation and commercialization. How are ideas created? How are ideas tested and implemented? How do ideas contribute to scientific knowledge? How are ideas marketed and sold?...
Good wood: making the most of forest resources
13.2.2012 | Newly on Gate2Biotech
The timber industry currently wastes huge amounts of precious wood by-products like chips, shavings and sawdust that could otherwise be put to use. European researchers, with the support of EU funding, are finding new ways to ensure every little bit counts.
Why the Bioeconomy matters?
8.2.2012 | Newly on Gate2Biotech
European Commission workshop outlines the Bioeconomy’s impact in our lives. Stirring lessons in science and innovation were delivered in Brussels on Tuesday February 7 at a European Commission workshop devoted to the Bioeconomy.
How to build career in Central European biotech sector
18.1.2012 | Newly on Gate2Biotech
HAYS Czech Republic, leading global experts in qualified in professional and skilled recruitment, joints to BioForum 2012 (www.cebioforum.com) event, held in Brno, Czech Republic May 23-24th, 2012 and organizes a career day oriented on pharmaceutical and biotech market.
Faster and cheaper. Central European CRO market
11.1.2012 | Newly on Gate2Biotech
Central Europe (CE) is becoming a new emerging market for CROs (Clinical Research Organizations). Fast growing outsourcing of clinical studies in CE region creates new opportunities for pharma and biotech companies facing with cost and time consuming process of drug delivery to the market.
“There is no success without defeat” – how to win in a high risk biotech enterprise
20.12.2011 | Newly on Gate2Biotech
Central Europe (CE) is an emerging biotech market, a small star among European regions. There are more or less 200 innovative biotech companies, which mostly were established in last 10 years. During the 11th edition of BioForum, Central European Forum of Biotechnology and Innovative BioEconomy, held in Brno, Czech Republic, May 23-24th 2012...
Integrate in your mindset the most compliant pharma packaging and labelling solutions for 2012!
5.12.2011 | Newly on Gate2Biotech
Anti-counterfeiting, packaging safely via redesign, 2D barcoding integrity and artwork management updates are just a few among the major themes of Fleming Europe’s 2nd Annual Pharma Packaging & Labeling Compliance Conference which is once again bringing you three days of ground-breaking debate and pioneering case studies from top industry,...
Writing Competitive Proposals: How to Succeed in FP7
16.11.2011 | Newly on Gate2Biotech
How to make your proposal succeed in Framework Programme 7? The crucial parameters are scientific quality of proposal, implementation plan and potential impact of the carried proposal. Seminar is focused on these problems.
